Tag: Covaxin

Covaxin manufacturer Bharat Biotech said its service provider, IQVIA, has started final statistical analysis.

With India ramping up the ongoing vaccination drive, the Central government on Tuesday (June 8) announced a price cap for the administration of Covid-19 vaccines in private hospitals

Noting that 60 per cent to 70 per cent of the children who got infected and got admitted in hospitals during the second wave in India, had either comorbidities or low immunity, the All India Institute of Medical Sciences (AIIMS) Director said that healthy children recovered with mild illness without need for hospitalisation.

The maximum price of Covishield for private COVID-19 Vaccination Centres (CVCs) has been fixed at Rs 780 per dose, while that of Covaxin is Rs 1,410 per dose and Sputnik V Rs 1,145 per dose, it said.

The series of lockdowns and shutdowns enforced by the State government of Odisha has really fructified results as anticipated, DMET CBK Mohanty said today.

The screening of children for trial of Covaxin, India's first indigenously developed COVID-19 vaccine, among those aged between 2 and 18 started at the AIIMS here on Monday.

A latest study has found that both vaccines, Covishield and Covaxin elicited a good immune response after two doses, although seropositivity rates and the median anti-spike antibody titre was significantly higher in Covishield as compared to Covaxin.

Amid apprehensions over children being more prone to the virus in the third wave, indigenous pharma company Bharat Biotech has started its clinical trials of COVAXIN on children at Patna's All India Institute of Medical Sciences (AIIMS) hospital in Bihar.

Admitting that the State Capital does not have enough doses of COVAXIN for the age group of 18-44, the Commissioner of Bhubaneswar Municipal Corporation (BMC), Sanjay Singh on Thursday assured that it will be made available soon.

The Bhubaneswar Municipal Corporation (BMC) on Monday launched doorstep Covid-19 vaccination drive under its jurisdiction to inoculate people above 45 years of age at their homes.

Naba Das on Friday urged the Centre to allow the surplus vaccines, which the State has in stock for the age group of 45 and above, to be diverted for a short term.

For vaccines to result in actual vaccination of people, highly coordinated efforts are required from international supply chain, manufacturers, regulators, and state and Central government agencies, it added.

"The World Health Organisation (WHO) has not taken any decision on banning people from travelling who have been vaccinated with Covaxin. Covaxin is the one of the most effective vaccines to date."

Bharat Biotech plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety. 

Peer-review publication, Clinical Infectious Diseases, has noted that Covaxin demonstrates protection against the new Covid-19 variants.